Показано 0 из 0
Дата |
---|
17.05.2024 |
16.05.2024 |
15.05.2024 |
14.05.2024 |
13.05.2024 |
10.05.2024 |
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.13
|
1.28
|
1.19
|
1.14
|
1.22
|
1.16
|
|
|
33 027.91
|
192.00
|
1.13
|
1.25
|
1.17
|
1.05
|
1.33
|
1.22
|
|
|
138 869.18
|
504.00
|
1.19
|
1.25
|
1.29
|
1.1301
|
1.29
|
1.19
|
|
|
25 681.62
|
239.00
|
1.16
|
1.29
|
1.26
|
1.2409
|
1.33
|
1.285
|
|
|
24 393.51
|
274.00
|
1.25
|
1.27
|
1.28
|
1.20
|
1.28
|
1.27
|
|
|
37 757.64
|
201.00
|
1.20
|
1.23
|
1.31
|
1.1802
|
1.32
|
1.24
|
|
|
58 972.27
|
272.00
|
0.90
|
1.60
|
1.3124
|
1.2774
|
1.42
|
1.33
|
|
|
39 518.47
|
198.00
|
1.29
|
1.56
|
1.30
|
1.29
|
1.35
|
1.32
|
|
|
18 106.55
|
153.00
|
1.00
|
1.24
|
1.32
|
1.25
|
1.381
|
1.30
|
|
|
58 262.42
|
312.00
|
1.26
|
1.55
|
1.28
|
1.2396
|
1.38
|
1.32
|
|
|
79 279.51
|
285.00
|
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, targeting common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR.